Tacrolimus Market Size, Share Trends Analysis Report, 2024-2032
Tacrolimus Market Size, Share Trends Analysis Report, 2024-2032

Tacrolimus Market Share, Size, Trends, Industry Analysis Report, By Product Type (Injections, Tablets and Capsules, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 203

  • Published Date:Feb-2024
  • Pages: 115
  • Format: PDF
  • Report ID: PM4519
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

Tacrolimus market size was valued at USD 6,521.57 million in 2023. The market is anticipated to grow from USD 6,801.35 million in 2024 to USD 9,683.26 million by 2032, exhibiting the CAGR of 4.5% during the forecast period

Tacrolimus Market Overview

The Tacrolimus market development is anticipated to grow significantly due to the increasing prevalence of venous diseases and the rising approvals of new products. The surge in awareness about the disease, increasing spending on chronic diseases, and the rising importance of early diagnosis are anticipated for the tacrolimus market growth. Further, the key players in the market are continuously investing in the research and development of technologically cutting-edge products, which leads to a rise in the utilization of tacrolimus products around the globe. Also, the rise in the number of organ transplants and a surge in immunosuppressive R&D are facilitating the tacrolimus market growth.

Tacrolimus Market Size

To Understand More About this Research: Request a Free Sample Report

  • For instance, 2022 According to the United Network for Organ Sharing (UNOS) report, the United States witnessed a total of 42,887 organ transplant procedures in the year 2022.

Tacrolimus is an immunosuppressive medication commonly used to prevent rejection in organ transplants. It inhibits the activity of certain immune cells, which reduces the likelihood of the body rejecting a transplanted organ. It can be utilized as an agent to prevent or treat specific autoimmune disorders.

Furthermore, advancements in pharmacogenomics have enabled medical professionals to personalize tacrolimus therapy to a patient's genome, thereby optimizing drug metabolism and reducing adverse reactions. These advances in transplantation medicine demonstrate the commitment to improving immunosuppressive strategies, ultimately improving long-term organ transplant success rates and transplant recipients' quality of life. The tacrolimus market growth demonstrates a collaborative effort to address the complexities of immunosuppression, fostering the desire for further advancements.

The tacrolimus market has witnessed a substantial rise in transplant indications, indicating a significant advancement in the field of organ transplantation. The growing acceptance of tacrolimus in a variety of transplant indications demonstrates the pharmaceutical industry's dedication to improving patient outcomes and pushing the boundaries of organ transplantation. Tacrolimus is anticipated to have a growing role in the rapidly evolving field of transplant medicine, providing new hope and opportunities for patients undergoing a broad spectrum of organ transplant procedures.

The COVID-19 pandemic has had a negative impact on the tacrolimus market. As the disease has spread over 100 + countries across the world, the World Health Organization (WHO) has declared a public health emergency on the 30 January 2020. Owing to the lockdown imposed by numerous governments across the world, the transportation of products has been stopped. Most of the patients were restricted from undergoing organ transplant procedures during the COVID period.

Tacrolimus Market Dynamics

Market Drivers

Increasing research and development activities drive the tacrolimus market growth

The rising research and development activities drive the tacrolimus market growth. The increased emphasis on research and development is encouraging the development of cutting-edge technologies, innovative products, and advanced solutions. Such initiatives not only improve the quality of existing offerings but also lead the path for groundbreaking innovations. Industries ranging from pharmaceuticals and technology to energy and manufacturing are undergoing positive transformations as a result of increased R&D efforts. The implementation of new ideas and the pursuit of innovative solutions aid Tacrolimus market growth by fulfilling changing consumer demands and staying ahead. Furthermore, the relationship between increased R&D activity and tacrolimus market growth illustrates the importance of cultivating an innovative culture in the current dynamic global economy.

The increasing prevalence of autoimmune diseases facilitating the growth of the market

The rising prevalence of autoimmune diseases facilitates the market. Tacrolimus is utilized to treat certain autoimmune illnesses, including atopic dermatitis and rheumatoid arthritis. As the prevalence of autoimmune disorders increases, the demand for immunosuppressive drugs such as tacrolimus. The growing patient population with autoimmune conditions drives tacrolimus market growth, as healthcare providers prescribe these medications to manage and control immune system responses.

Pharmaceutical companies and research organizations are actively developing innovative drugs and therapies to treat autoimmune disorders. Precision medicine, biologics, and targeted therapies are driving advancements in this market, providing patients with more tailored and effective solutions. As diagnostic capabilities improve and awareness of autoimmune diseases increases, the market is anticipated to grow, indicating a concerted effort to meet the changing healthcare needs of people living with these complex and often debilitating conditions.

Market Restraints

Side effects and the availability of the alternative treatments hampering on the tacrolimus market growth

The side effects associated with the availability of alternative treatments hamper the tacrolimus market growth. Tacrolimus can cause serious side effects such as discomfort or burning during urination, decreased urine output, pale skin, a rapid heartbeat, shortness of breath, and even coma (temporary loss of consciousness). The most common side effects of tacrolimus are nausea, headaches, diarrhea, and constipation. These substitutes offer comparable therapeutic benefits, decreasing the demand for tacrolimus. Cost, efficacy, and patient preferences are all important considerations when selecting immunosuppressive drugs. As a result, the presence of viable alternatives will hinder the growth of the tacrolimus market.

Report Segmentation

The market is primarily segmented based on product type, application, end-use, and region.

By Product Type

By Application

By End-Use

By Region

  • Injections
  • Tablets and Capsules
  • Others


  • Dermatitis
  • Immunosuppression
  • Others
  • Clinics
  • Hospitals
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

Tacrolimus Market Segmental Analysis

By Product Type Analysis

  • The tablets and capsules segment held the largest market share in 2023. Tablets and capsules improve patient compliance with medication regimens, which is crucial for the effectiveness of immunosuppressant therapy.

By Application Analysis

  • The immunosuppression segment held the largest market share in 2023. Immunosuppressive medications are crucial for preventing organ rejection in transplant recipients. The increasing prevalence of organ transplant procedures contributes to rising demand for these drugs during the forecast period.

By End-Use Analysis

  • Based on end-use analysis, the market has been segmented on the basis of clinics, hospitals, and others. The hospital segment dominated the market with largest revenue share in 2023. The presence of dedicated transplant facilities in medical institutions generally leads to an increase in the frequency of transplant surgeries, which raises the need for tacrolimus. Additionally, government initiatives that promote organ transplantation and provide financial assistance for immunosuppressant medications contribute to increased demand within healthcare facilities.

Tacrolimus Market Regional Insights

North America dominated the largest market in 2023

North America dominated the tacrolimus market due to factors such as increased tacrolimus awareness, a rise in organ transplantation, and the presence of key manufacturers in the region. For instance, The Health Resources and Services Administration predicts that more than 40,000 transplant procedures will be performed in the United States in 2021. At the same time, 90,483 people were waiting for organ transplants.

Furthermore, with 90,483 people awaiting organ transplants, the demand for tacrolimus medications is anticipated to increase. This increase in demand is owing to an increase in the number of transplant surgeries, which is driving the tacrolimus market growth in North America.

Competitive Landscape

The tacrolimus market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.

Some of the major players operating in the global market include:

  • Astellas Pharma Inc.
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Novartis AG
  • Lupin Pharmaceuticals Inc.
  • Panacea Biotec
  • Pfizer Inc.

Recent Developments

  • In November 2020, Lupin Limited launched Tacrolimus Capsules USP in 0.5 mg, 1 mg, and 5 mg strengths, serving as the generic counterpart to Astellas Pharma's Prograf Capsules. This launch follows the approval of the Abbreviated New Drug Application (ANDA) by Lupin's collaborative partner, Concord Biotech Limited, from the United States Food and Drug Administration.

Report Coverage

The tacrolimus market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product type, application, end-use, and their futuristic growth opportunities.

Tacrolimus Market Report Scope

Report Attributes


Market size value in 2024

USD 6,801.35 million

Revenue forecast in 2032

USD 9,683.26 million


4.5% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

By Product Type, By Application, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation


Astellas Pharma Inc., Biocon Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Inc are the key companies in Tacrolimus Market.

Tacrolimus market is CAGR of 4.5% during the forecast period

The Tacrolimus Market report covering key segments are type, application, end-use, and region.

Increasing research and development activities drive the tacrolimus market growth are the key driving factors in Tacrolimus Market

The tacrolimus market size is expected to reach USD 9,683.26 million by 2032